Tysabri Cost Data Shows Up To $23,274 Benefit Over Other MS Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec/Elan report data showing a treatment cost benefit with Tysabri based on multiple sclerosis relapses avoided.
You may also be interested in...
Tysabri Re-Launches In U.S. Through Single Distributor
Biogen Idec/Elan's multiple sclerosis therapy Tysabri is available in the U.S. through a single distributor: AmerisourceBergen Specialty Group division ICS
ICER Hands CMS A Drug Price Negotiation Cheat Sheet
The drug price assessment group ran cost analyses on two of the first 10 drugs selected for Medicare price negotiations, Eliquis and Xarelto, and submitted the report to the US government.
Blueprint’s Evolution On Its Path To Financial Sustainability
Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.